Loading stock data…
$5.38+0.04 (+0.65%)
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Cytek Biosciences, Inc. in the Healthcare sector is trading at $5.38 with a market capitalization of $602M. Wall Street consensus targets $5.56 (4 analysts), implying a +3.3% move over the next 12 months. The stock is currently 13% below its 52-week high of $6.21, remaining 16.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $48.14M↑ | $44.13M↓ | $62.14M↑ | $52.29M↑ | $45.60M |
| Gross Profit | $28.34M↑ | $21.25M↓ | $32.88M↑ | $27.55M↑ | $23.87M |
| Operating Income | -$11.40M↑ | -$18.46M↓ | -$5.59M↑ | -$9.19M↑ | -$10.62M |
| Net Income | -$12.16M↑ | -$18.87M↑ | -$44.08M↓ | -$5.48M↑ | -$5.58M |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora ...